Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Alfacalcidol for secondary hyperparathyroidism after Roux-en-Y gastric bypass
NL-OMON53666Recruiting
- Sponsor
- Leiden University Medical Center
- Start
- Dec 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Randomised, open-label trial of alfacalcidol in secondary hyperparathyroidism (SHPT) (2 arms), sponsored by Leiden University Medical Center. Primary endpoint: Normalization of parathyroid hormone. Started Dec 2023; status: recruiting.
02
Drugs
alfacalcidol
03
Conditions
secondary hyperparathyroidism (SHPT)
Beyond the preview
Go deeper on NL-OMON53666.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON53666.